1. Sep 22, 2015

    C4 Imaging Utilizes Evonik’s VESTAKEEP® PEEK For Prostate Cancer Device (PDF)

    C4 Imaging LLC has chosen leading specialty chemicals company Evonik Corporation and its Resource Efficiency segment’s VESTAKEEP® PEEK polymer technology in the design of Sirius, a recently developed Positive-Signal Magnetic Resonance Imaging (MRI) Marker used during the treatment of prostate cancer.

  2. Aug 21, 2015

    C4 Imaging Awarded $1.3 Million NIH SBIR Phase II Grant (PDF)

    C4 Imaging LLC today announced it has been awarded a $1.32 Million Phase II Small Business Innovation Research (“SBIR”) grant from the National Cancer Institute of the National Institutes of Health (“NIH”). Entitled “Multi-Modality MRI/CT Markers for Improved Assessment of Prostate Cancer”, the Phase II SBIR award will help fund the development of an enhanced multi-modality imaging marker based on C4 Imaging’s commercially available Sirius MRI Marker.

  3. Apr 7, 2014

    C4 Imaging Announces First SIRIUS Positive Signal MRI Marker Implant (PDF)

    “This first implant is a significant milestone,” said Andrew Bright, President and CEO of C4 Imaging. “MR imaging of the implanted Sirius MRI Markers was successful and the clinical team were able to localize the implanted seeds.” He added, “We were delighted to partner with IsoRay™ Medical for this first implant.

  4. Mar 31, 2014

    C4 Imaging Signs SIRIUS MRI MARKER Loading Services Agreement with AnazaoHealth Corporation (PDF)

    C4 Imaging will partner with Florida-based AnazaoHealth Corporation, a leading provider of patient-specific prescription-loaded brachytherapy products for treating prostate cancer. Under the agreement AnazaoHealth will load the Sirius MRI Marker alongside seeds into brachytherapy strands and needles according a physician prescription tailored to each individual patient.

  5. Dec 6, 2013

    C4 Imaging Announces FDA 510(k) Clearance of its Positive-Signal MRI Marker - Sirius (PDF)

    C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius MRI Marker. The novel positive-signal, MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance (MR) imaging procedure.